Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Common Equity (2016 - 2025)

BioCorRx's Common Equity history spans 16 years, with the latest figure at -$12.8 million for Q3 2025.

  • For Q3 2025, Common Equity fell 6.34% year-over-year to -$12.8 million; the TTM value through Sep 2025 reached -$12.8 million, down 6.34%, while the annual FY2024 figure was -$12.1 million, 221.78% down from the prior year.
  • Common Equity for Q3 2025 was -$12.8 million at BioCorRx, down from $13.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $13.0 million in Q2 2025 and bottomed at -$12.8 million in Q3 2025.
  • The 5-year median for Common Equity is -$7.5 million (2022), against an average of -$5.3 million.
  • The largest annual shift saw Common Equity surged 221.35% in 2023 before it tumbled 221.78% in 2024.
  • A 5-year view of Common Equity shows it stood at -$7.0 million in 2021, then dropped by 17.82% to -$8.2 million in 2022, then soared by 221.35% to $10.0 million in 2023, then crashed by 221.78% to -$12.1 million in 2024, then fell by 5.31% to -$12.8 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Common Equity are -$12.8 million (Q3 2025), $13.0 million (Q2 2025), and $11.8 million (Q1 2025).